Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive eith...

Full description

Bibliographic Details
Main Authors: Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, Matthias Borowski, Caroline Forner, Joachim Gerss, Martin Metz, Petra Staubach, Ulrike Raap, Martin Kaatz, Marc Urban, Thomas A. Luger, Sonja Ständer
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2019-02-01
Series:Acta Dermato-Venereologica
Subjects:
pruritus
itch
chronic nodular prurigo
substance P
neurokinin receptor 1
NK1 antagonist
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3120

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3120

Similar Items